ClinicalTrials.gg
Not yet recruitingNCT07366632Updated Jan 26, 2026

A Study of Single Dose of BL0175 in Postmenopausal Women

A Phase 1 interventional study of BL0175 and Fulvestrant in Postmenopausal Women, sponsored by Shanghai Best-Link Bioscience, LLC. Not yet recruiting. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Shanghai Best-Link Bioscience, LLC · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this clinical trial is to learn the safety and PK of the single dose of BL0175 Injection in postmenopausal women and to compare that with a single dose of Fulvestrant Injection. The main questions it aims to answer are:

  • What medical problems do participants have when using drug BL0175?
  • How long can BL0175 remain in your blood? Participants will receive a single dose of drug BL0175 or a single dose of Fulvestrant Injection in a randomized method
02

Conditions studied

  • Postmenopausal Women
03

In context

Lead sponsor

Shanghai Best-Link Bioscience, LLC is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteer to participate in the study, be able to understand the requirements of a clinical study, and sign form.
  2. female participants aged ≥ 18 years old.
  3. Body weight ≥ 45kg and (BMI= weight/height2) scores ≥ 18 kg/m2 and ≤ 35 kg/m2.
  4. Participants with laboratory tests, physical examinations, vital signs, and (ECG) results judged by the investigator as normal or abnormal with no clinical significance (NCS).

Exclusion criteria

Exclusion Criteria:

  1. Participants with a history or current presence of any cardiovascular, gastrointestinal, endocrine, hematological, hepatic, immunological, metabolic, urinary, pulmonary, neurological, dermatological, psychiatric, renal, and/or other major diseases that are considered by the investigator.
  2. A history of allergy to fulvestrant, alcohol, castor oil, benzyl alcohol, benzyl benzoate or any other comparable or similar products, or prone to allergic reactions (such as: prone to angioedema, urticaria, asthma, rash, etc.), or history of allergy to two or more drugs (or foods).
  3. Participants with current concomitant sciatica, neuralgia, or peripheral neuropathy.
  4. History of transplantation of organs, bone marrow or stem cell.
  5. Active infection, a known history of virus (HBV), virus (HCV) or (HIV) infection or screening for infectious disease (HBsAg, hepatitis C virus antibody [HCV-Ab], or human immunodeficiency virus antigen/antibody [HIV-Ag/Ab]) during the screening period is positive.
  6. Unable to refrain from or anticipate the use of any prescription medications not for the treatment of concomitant diseases within 4 weeks prior to administration, or any over-the-counter drugs (including but not limited to Chinese herbal medicines, compound preparations of Chinese herbal medicines, health products, etc.) not for the treatment of concomitant diseases within 2 weeks prior to administration.
  7. Participants who are vaccinated within 14 days prior to dosing administration.
  8. Those who donated plasma or blood within 12 weeks prior to the dosing administration or donated or lost blood 400 mL or more within 12 weeks prior to the dosing administration, or plan to donate during the study.
  9. Any history of coagulation dysfunction, bleeding diathesis (e.g., disseminated intravascular coagulation, coagulation factor deficiencies), long-term anticoagulant therapy (excluding antiplatelet therapy and low-dose warfarin), active bleeding (such as gastrointestinal bleeding), or clinically significant thrombocytopenia.
  10. Intolerance to / fear of venipuncture, needles, or blood collection difficulties (such as poor vascular conditions, fear of blood collection, needle dizziness, etc.).
  11. Those who underwent major surgery within 4 weeks before screening, or plan to undergo major surgery during the study.
  12. Those who have taken/used drugs, vaccines or devices within the 4 weeks or 5 half-lives of investigational drug (whichever is longer) prior to the dosing administration.
  13. Participants who with a history of alcoholism, or with a history of alcohol abuse within 3 months prior to screening (by self-declaration) > 14 alcohol units per week (1 alcohol unit is about equal to 50° white wine 35 mL or 5° beer 350 mL or wine 150 mL). Participants are unable/unwilling to refrain from alcohol, or strenuous exercise 48 hours prior to each study visit.
  14. Participants who with a history of drug abuse or drug dependence, or those who have used illicit drugs within 1 year prior to screening.
  15. Positive alcohol or drug screen results at Baseline.
  16. Those who are determined by the investigator to be ineligible for other reasons.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    BL0175 250mg

    Drug: BL0175

  • Active comparator
    Fulcestrant 250mg

    Drug: Fulvestrant

Interventions

  • DrugBL0175

    BL0175 is a polymer-drug conjugate, composed of a steroidal estrogen receptor antagonist fulvestrant covalently linked to a PEG-modified poly- polymer via a peptide based cleavable linker

  • Fulvestrant Injection has been marked in many country and regions for the treatment of women who have been through menopause with: * hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer who have not been previously treated with endocrine therapy. * HR positive, locally advanced or metastatic breast cancer who have progressive disease following prior endocrine (anti-oestrogen or aromatase inhibitor) therapy. Fulvestrant stops some of the actions of oestrogen within the body. Oestrogen is a female sex hormone that may help cancer cells grow in women with breast cancer.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events as assessed by CTCAE v6.0

    Time frame: from Day 1 to Day 57

Secondary outcomes

  1. Pharmacokinetics (PK) parameters-Maximum concentration (Cmax) of fulvestrant

    Time frame: From Day 1 to Day 197

  2. Serious adverse events (SAE) that related to investigational product

    Time frame: up to 197 days

  3. Pharmacokinetics (PK) parameters-Area under the concentration curve (AUC) of fulvestrant

    Time frame: From Day 1 to Day 197

  4. Half-life (t1/2)of fulvestrant

    Time frame: From Day 1 to Day 197

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for May 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 26, 2026
StartEst.
Jan 26, 2026
Primary completionEst.
May 8, 2026
CompletionEst.
Dec 21, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07366632
Lead sponsor
Shanghai Best-Link Bioscience, LLC
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
Jan 26, 2026 (estimated)
Primary completion
May 8, 2026 (estimated)
Completion
Dec 21, 2026 (estimated)
Last update
Jan 26, 2026

Study contacts

Fang
Contact
fangzhuolun@bestlinkbio.com
+86 18357916536

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BL0175

Start the discussion